Response Rates to Targeted Therapy

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course . Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about (online CE course)
Response Rates to Targeted Therapy

Research data has shown that tamoxifen therapy prolonged both disease-free periods and also overall survival rates in patients with estrogen receptor (ER)-positive breast tumors, but had little benefit for patients who had ER-negative tumors. In addition, patients who were ER-negative, but progesterone receptor (PR)-positive, also improved with tamoxifen therapy.